These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 8719152)
1. Problems in assessing screening experience in observational studies of screening efficacy: example of urinalysis screening for bladder cancer. Friedman GD; Hiatt RA; Quesenberry CP; Selby JV; Weiss NS J Med Screen; 1995; 2(4):219-23. PubMed ID: 8719152 [TBL] [Abstract][Full Text] [Related]
2. Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker. Lotan Y; Elias K; Svatek RS; Bagrodia A; Nuss G; Moran B; Sagalowsky AI J Urol; 2009 Jul; 182(1):52-7; discussion 58. PubMed ID: 19450825 [TBL] [Abstract][Full Text] [Related]
3. Utility of serial urinalyses and urinary cytology in the evaluation of patients with microscopic haematuria. Rosser CJ; Nakamura K; Pendleton J; Anal S; Chang M; Kasraelan A; Yeung L West Afr J Med; 2010; 29(6):384-7. PubMed ID: 21465445 [TBL] [Abstract][Full Text] [Related]
4. The role of haematuria in bladder cancer screening among men with former occupational exposure to aromatic amines. Pesch B; Nasterlack M; Eberle F; Bonberg N; Taeger D; Leng G; Feil G; Johnen G; Ickstadt K; Kluckert M; Wellhäusser H; Stenzl A; Brüning T; BJU Int; 2011 Aug; 108(4):546-52. PubMed ID: 21223477 [TBL] [Abstract][Full Text] [Related]
5. Can hematuria be a predictor as well as a symptom or sign of bladder cancer? Friedman GD; Carroll PR; Cattolica EV; Hiatt RA Cancer Epidemiol Biomarkers Prev; 1996 Dec; 5(12):993-6. PubMed ID: 8959322 [TBL] [Abstract][Full Text] [Related]
6. Outcomes of a bladder cancer screening program using home hematuria testing and molecular markers. Bangma CH; Loeb S; Busstra M; Zhu X; El Bouazzaoui S; Refos J; Van Der Keur KA; Tjin S; Franken CG; van Leenders GJ; Zwarthoff EC; Roobol MJ Eur Urol; 2013 Jul; 64(1):41-7. PubMed ID: 23478169 [TBL] [Abstract][Full Text] [Related]
7. Yield of Urinalysis Screening in Pediatric Cancer Survivors. Ramirez MD; Mertens AC; Esiashvili N; Meacham LR; Wasilewski-Masker K Pediatr Blood Cancer; 2016 May; 63(5):893-900. PubMed ID: 26797960 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic. Blick CG; Nazir SA; Mallett S; Turney BW; Onwu NN; Roberts IS; Crew JP; Cowan NC BJU Int; 2012 Jul; 110(1):84-94. PubMed ID: 22122739 [TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes in a high-risk bladder cancer screening cohort. Starke N; Singla N; Haddad A; Lotan Y BJU Int; 2016 Apr; 117(4):611-7. PubMed ID: 25891519 [TBL] [Abstract][Full Text] [Related]
10. Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study. Huber S; Schwentner C; Taeger D; Pesch B; Nasterlack M; Leng G; Mayer T; Gawrych K; Bonberg N; Pelster M; Johnen G; Bontrup H; Wellhäusser H; Bierfreund HG; Wiens C; Bayer C; Eberle F; Scheuermann B; Kluckert M; Feil G; Brüning T; Stenzl A; BJU Int; 2012 Sep; 110(5):699-708. PubMed ID: 22313585 [TBL] [Abstract][Full Text] [Related]
11. Defining Properly Collected Urine: Thresholds to Improve the Accuracy of Urinalysis for Microscopic Hematuria Evaluation in Women. Chen A; Caron A; Jackson NJ; Kanji F; Kuhlmann P; Le CH; Eilber KS; Anger JT; Ackerman AL J Urol; 2022 Feb; 207(2):385-391. PubMed ID: 34544262 [TBL] [Abstract][Full Text] [Related]
12. Tracking unnecessary negative urinalyses to reduce healthcare costs: a transversal study. Malmartel A; Dutron M; Ghasarossian C Eur J Clin Microbiol Infect Dis; 2017 Sep; 36(9):1559-1563. PubMed ID: 28357510 [TBL] [Abstract][Full Text] [Related]
13. Cigarette smoking and bladder cancer in Washington County, Maryland: ammunition for health educators. McCarthy PV; Bhatia AJ; Saw SM; Mosley JD; Vega-Quiñones A Md Med J; 1995 Dec; 44(12):1039-42. PubMed ID: 8544669 [TBL] [Abstract][Full Text] [Related]
15. NMP-22 for bladder cancer screening and surveillance. Gray M; Sims TW Urol Nurs; 2004 Jun; 24(3):171-2, 177-9, 186. PubMed ID: 15311485 [TBL] [Abstract][Full Text] [Related]
16. Diagnostics: A flow of information. Wald C Nature; 2017 Nov; 551(7679):S48-S50. PubMed ID: 29117161 [No Abstract] [Full Text] [Related]
17. Prospective evaluation of fluorescence-in situ-hybridization to detect bladder cancer: results from the UroScreen-Study. Banek S; Schwentner C; Täger D; Pesch B; Nasterlack M; Leng G; Gawrych K; Bonberg N; Johnen G; Kluckert M; Gakis G; Todenhöfer T; Hennenlotter J; Brüning T; Stenzl A; Urol Oncol; 2013 Nov; 31(8):1656-62. PubMed ID: 22621963 [TBL] [Abstract][Full Text] [Related]
18. The significance of cystoscopy for the diagnosis of urothelial tumour. Hattori R; Ohshima S; Ono Y; Miyake K Int Urol Nephrol; 1993; 25(2):135-9. PubMed ID: 8365842 [TBL] [Abstract][Full Text] [Related]
19. A case-control study to evaluate efficacy of screening for faecal occult blood. Lazovich D; Weiss NS; Stevens NG; White E; McKnight B; Wagner EH J Med Screen; 1995; 2(2):84-9. PubMed ID: 7497161 [TBL] [Abstract][Full Text] [Related]
20. The admission urinalysis: impact on patient care. Kroenke K; Hanley JF; Copley JB; Matthews JI; Davis CE; Foulks CJ; Carpenter JL J Gen Intern Med; 1986; 1(4):238-42. PubMed ID: 3772598 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]